TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03525548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445/TEZ/IVA
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Participants received TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Study: NCT00628797

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA1
Description: intraindividual half body irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVA1
Description: 60 J/cm2 at least 36 tx

Intervention type: OTHER
Group type: OTHER
Intervention: UVA1
Description: 60 J/cm2 at least 36 tx
Study: NCT02094014

Intervention type: BEHAVIORAL
Intervention: Normal Auditory Feedback
Description: Participants will produce sentences under normal speaking conditions, able to hear their own speech.

Intervention type: BEHAVIORAL
Intervention: Normal Auditory Feedback
Description: Participants will produce sentences under normal speaking conditions, able to hear their own speech.

Intervention type: BEHAVIORAL
Intervention: Masked Auditory Feedback
Description: Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.

Intervention type: BEHAVIORAL
Intervention: Masked Auditory Feedback
Description: Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.

Intervention type: BEHAVIORAL
Intervention: Altered Auditory Feedback
Description: Participants will produce sentences while listening to their speech shifted up one octave and delayed.
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Once daily dose of abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Once daily dose of abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Once daily dose of abiraterone acetate
Study: NCT02094014

Intervention type: BEHAVIORAL
Intervention: Altered Auditory Feedback
Description: Participants will produce sentences while listening to their speech shifted up one octave and delayed.
Study: NCT03152955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be applied in patient-controlled analgesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp nerve block
Description: Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ondansetron
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
Study: NCT03331484

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
Study: NCT02295514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTP1B dosage
Description: PTP1B sampled and dosed during sepsis
Study: NCT01551602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK159
Description: transdermal administration of teriparatide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-10-T
Description: subcutaneous administration of teriparatide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-10-T
Description: subcutaneous administration of teriparatide acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple administration of placebo AK159
Study: NCT03917004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level.
Study: NCT01662063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
Study: NCT02127086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
Study: NCT04543006

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serology
Description: blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Study: NCT01266499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: will not receive PO treatment
Description: will not receive PO treatment - will receive plecebo treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Garamycin 80mg x 4/d
Description: PO Garamycin 80mg x 4/d
Study: NCT06326216

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT01740999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: silicone arthroplasty
Description: silicone arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrodesis
Description: arthrodesis
Study: NCT01894256

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Study: NCT02511171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulative therapy
Study: NCT00314925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seneca Valley Virus (biological agent)
Description: Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
Study: NCT05181514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Description: Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
Study: NCT03215901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Beautiful Future Video
Description: Video delivering information on the longevity gains due to HIV treatment in the area.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Active Control Video
Description: Video on another topic.
Study: NCT03889626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 500mg qd po, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid po, d1-14, q3w
Study: NCT03938415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized pre-procedure medications
Description: The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
Study: NCT03117595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: Dosages as previously written

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl morphine
Description: Dosage as previously written
Study: NCT02207062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02923739

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04026165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SEL
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally once daily
Study: NCT02179502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 single ascending doses
Description: Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses
Description: Single dose, oral suspension or solid formulation matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Study: NCT02929433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycloergometer
Description: Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
Study: NCT04387630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Simethicone 60 mg three times daily.
Study: NCT02573402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation
Description: 10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
Study: NCT02623855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family outings
Description: Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Park prescription
Description: Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park prescription
Description: Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometry
Description: Participants will record their daily pedometry.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometry
Description: Participants will record their daily pedometry.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
Study: NCT05264532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information-graphic video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive family letter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03155620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT02552693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced training, supervision and support
Description: The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities.
Study: NCT04747717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy/surgery
Description: NEO chemotherapy/interval debulking surgery/AD chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy/surgery
Description: NEO chemotherapy/interval debulking surgery/AD chemotherapy
Study: NCT03465670

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHX
Description: Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHX+HA+ADS
Description: Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
Study: NCT01699581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Impact Advanced Recovery
Description: dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
Study: NCT02477566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting Triptorelin
Description: Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting Triptorelin
Description: Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
Study: NCT04152928

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
Study: NCT02243956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol rich food product
Description: polyphenol rich test product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol rich food product
Description: polyphenol rich test product